Directorate Change

Oxford Biomedica PLC
12 May 2004


For Immediate Release                                              12 May 2004




                                OXFORD BIOMEDICA PLC


                   APPOINTMENT OF SENIOR INDEPENDENT DIRECTOR


Oxford, UK: 12 May 2004 - Oxford BioMedica (LSE:OXB.L), the leading gene therapy
company, announces the appointment of Nick Rodgers as Senior Independent
Director of OXB, in compliance with the new Combined Code.


Nick Rodgers joined the Board of OXB as non-executive director on 2 March 2004.


-Ends-

For further information, please contact:
Oxford BioMedica plc
----------------------

Professor Alan Kingsman, Chief Executive               Tel: [phone]

                                       ---
City/Financial Enquiries:                              Tel: [phone]
Lisa Baderoon/ Mark Court: Buchanan Communications


Notes to editors


1. Oxford BioMedica


Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.


In addition to its technical expertise in gene delivery, Oxford BioMedica has
in-house clinical, regulatory and manufacturing know-how. The development
pipeline includes two novel anti-cancer products in clinical trials; and two
neurotherapy products in advanced preclinical development for Parkinson's
disease and retinopathy. The Company is underpinned by an extensive preclinical
and research portfolio and about 70 patent families, which represents one of the
broadest patent estates in the field.


The Company has a staff of 65 split between its main facilities in Oxford and
its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford
BioMedica has corporate collaborations with Wyeth, Intervet, Merck & Co,
Amersham and Kiadis.


Further information is available at http://www.oxfordbiomedica.co.uk









                      This information is provided by RNS
            The company news service from the London Stock Exchange